Literature DB >> 24307585

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Florian Krammer1, Irina Margine, Rong Hai, Alexander Flood, Ariana Hirsh, Vadim Tsvetnitsky, Dexiang Chen, Peter Palese.   

Abstract

The recent outbreak of H7N9 influenza virus infections in humans in China has raised concerns about the pandemic potential of this strain. Here, we test the efficacy of H3 stalk-based chimeric hemagglutinin universal influenza virus vaccine constructs to protect against H7N9 challenge in mice. Chimeric hemagglutinin constructs protected from viral challenge in the context of different administration routes as well as with a generic oil-in-water adjuvant similar to formulations licensed for use in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307585      PMCID: PMC3911549          DOI: 10.1128/JVI.03183-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  A highly conserved neutralizing epitope on group 2 influenza A viruses.

Authors:  Damian C Ekiert; Robert H E Friesen; Gira Bhabha; Ted Kwaks; Mandy Jongeneelen; Wenli Yu; Carla Ophorst; Freek Cox; Hans J W M Korse; Boerries Brandenburg; Ronald Vogels; Just P J Brakenhoff; Ronald Kompier; Martin H Koldijk; Lisette A H M Cornelissen; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Ian A Wilson; Jaap Goudsmit
Journal:  Science       Date:  2011-07-07       Impact factor: 47.728

Review 2.  The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

Authors:  Derek T O'Hagan; Gary S Ott; Gary Van Nest; Rino Rappuoli; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

3.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

4.  Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.

Authors:  Taia T Wang; Gene S Tan; Rong Hai; Natalie Pica; Erin Petersen; Thomas M Moran; Peter Palese
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

5.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

6.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

7.  H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Authors:  Irina Margine; Rong Hai; Randy A Albrecht; Gerlinde Obermoser; A Carson Harrod; Jacques Banchereau; Karolina Palucka; Adolfo García-Sastre; Peter Palese; John J Treanor; Florian Krammer
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

8.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Authors:  Natalie Pica; Rong Hai; Florian Krammer; Taia T Wang; Jad Maamary; Dirk Eggink; Gene S Tan; Jens C Krause; Thomas Moran; Cheryl R Stein; David Banach; Jens Wrammert; Robert B Belshe; Adolfo García-Sastre; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

9.  H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.

Authors:  M Anthony Moody; Ruijun Zhang; Emmanuel B Walter; Christopher W Woods; Geoffrey S Ginsburg; Micah T McClain; Thomas N Denny; Xi Chen; Supriya Munshaw; Dawn J Marshall; John F Whitesides; Mark S Drinker; Joshua D Amos; Thaddeus C Gurley; Joshua A Eudailey; Andrew Foulger; Katherine R DeRosa; Robert Parks; R Ryan Meyerhoff; Jae-Sung Yu; Daniel M Kozink; Brice E Barefoot; Elizabeth A Ramsburg; Surender Khurana; Hana Golding; Nathan A Vandergrift; S Munir Alam; Georgia D Tomaras; Thomas B Kepler; Garnett Kelsoe; Hua-Xin Liao; Barton F Haynes
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

10.  A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

Authors:  Florian Krammer; Irina Margine; Gene S Tan; Natalie Pica; Jens C Krause; Peter Palese
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

View more
  60 in total

1.  Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Authors:  Chi-Jene Chen; Megan E Ermler; Gene S Tan; Florian Krammer; Peter Palese; Rong Hai
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza.

Authors:  Veronika I Zarnitsyna; Ali H Ellebedy; Carl Davis; Joshy Jacob; Rafi Ahmed; Rustom Antia
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

Review 4.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

5.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Authors:  Wenqian He; Gene S Tan; Caitlin E Mullarkey; Amanda J Lee; Mannie Man Wai Lam; Florian Krammer; Carole Henry; Patrick C Wilson; Ali A Ashkar; Peter Palese; Matthew S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

Review 6.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

7.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

8.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 9.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

Review 10.  Mammalian models for the study of H7 virus pathogenesis and transmission.

Authors:  Jessica A Belser; Terrence M Tumpey
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.